Replies to post #4571 on Dendreon Corp fka DNDNQ

[nyseman_7]

SEATTLE, July 17, 2007 /PRNewswire-FirstCall via COMTEX/ --
Dendreon Corporation
(Nasdaq: DNDN) today announced the Company will release its second quarter
financial results on Tuesday, August 7, 2007. Company management will host a
conference call at 1:30 PM Pacific Time to provide a review of its second
quarter financial results and the following recent events.

* The Company received confirmation that the U.S. Food and Drug
Administration will accept either a positive interim or final analysis of
survival from its ongoing IMPACT study to amend the Biologics License
Application for Provenge(R) (sipuleucel-T), its investigational active
cellular immunotherapy for metastatic, androgen-independent prostate cancer.

* The Company continues to have strong patient enrollment in its Phase 3
IMPACT study, which is on track for completion of enrollment this year.

* The Company completed a financing that resulted in gross proceeds of
approximately $85 million from a convertible senior subordinated notes
offering.

* Presented data from an analysis of Phase 3 Studies (D9901 and D9902A)
that showed a prolonged survival benefit for patients who were initially
treated with PROVENGE who then went on to receive docetaxel chemotherapy after
disease progression.
Time: 4:30 PM ET /1:30 PM PT
Date: Tuesday, August 7, 2007
Dial-in: 1-800-665-0430 (domestic) or [phone] (international)
Webcast: http://www.dendreon.com (homepage and investor relations section)